Hesperidin Suppressed Colorectal Cancer through Inhibition of Glycolysis.
10.1007/s11655-024-4113-x
- Author:
Ke-Xiang SUN
1
;
Wei-Shan TAN
1
;
Hao-Yue WANG
1
;
Jia-Min GAO
1
;
Shu-Yun WANG
1
;
Man-Li XIE
1
;
Wan-Li DENG
2
,
3
Author Information
1. Department of Medical Oncology, Putuo Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, 200062, China.
2. Department of Medical Oncology, Putuo Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, 200062, China. tcmdwl@
3. com.
- Publication Type:Journal Article
- Keywords:
Chinese medicine;
Warburg effect;
colorectal cancer;
glycolysis;
hesperidin
- MeSH:
Hesperidin/therapeutic use*;
Colorectal Neoplasms/metabolism*;
Glycolysis/drug effects*;
Animals;
Humans;
Apoptosis/drug effects*;
Mice, Nude;
Cell Movement/drug effects*;
Cell Line, Tumor;
Cell Proliferation/drug effects*;
Glucose/metabolism*;
Cell Cycle/drug effects*;
Mice, Inbred BALB C;
Mice;
HCT116 Cells;
Lactic Acid
- From:
Chinese journal of integrative medicine
2025;31(6):529-540
- CountryChina
- Language:English
-
Abstract:
OBJECTIVE:To explore the role of the natural compound hesperidin in glycolysis, the key ratelimiting enzyme, in colorectal cancer (CRC) cell lines.
METHODS:In vitro, HCT116 and SW620 were treated with different doses of hesperidin (0-500 µmol/L), cell counting kit-8 and colone formation assays were utilized to detected inhibition effect of hesperidin on CRC cell lines. Transwell and wound healing assays were performed to detect the ability of hesperidin (0, 25, 50 and 75 µmol/L) to migrate CRC cells. To confirm the apoptotic-inducing effect of hesperidin, apoptosis and cycle assays were employed. Western blot, glucose uptake, and lactate production determination measurements were applied to determine inhibitory effects of hesperidin (0, 25 and 50 µmol/L) on glycolysis. In vivo, according to the random number table method, nude mice with successful tumor loading were randomly divided into vehicle, low-dose hesperidin (20 mg/kg) and high-dose hesperidin (60 mg/kg) groups, with 6 mice in each group. The body weights and tumor volumes of mice were recorded during 4-week treatment. The expression of key glycolysis rate-limiting enzymes was determined using Western blot, and glucose uptake and lactate production were assessed. Finally, protein interactions were probed with DirectDIA Quantitative Proteomics, Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) analyses.
RESULTS:Hesperidin could inhibit CRC cell line growth (P<0.05 or P<0.01). Moreover, hesperidin presented an inhibitory effect on the migrating abilities of CRC cells. Hesperidin also promoted apoptosis and cell cycle alterations (P<0.05). The immunoblotting results manifested that hesperidin decreased the levels of hexokinase 2, glucose transporter protein 1 (GLUT1), GLUT3, L-lactate dehydrogenase A, 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 2 (PFKFB2), PFKFB3, and pyruvate kinase isozymes M2 (P<0.01). It remarkably suppressed tumor xenograft growth in nude mice. GO and KEGG analyses showed that hesperidin treatment altered metabolic function.
CONCLUSION:Hesperidin inhibits glycolysis and is a potential therapeutic choice for CRC treatment.
